The treatment schedule of a single priming dose of tremelimumab (300 mg flat dose) combined with three doses of durvalumab (1500 mg flat dose q 4 weeks) was selected since the recently-presented D4190C00022 study showed that this schedule is endowed with the best benefit-to-risk profile and increases the proliferative CD8-positive T cells, potentially associated with tumor response [38]. Here, CD8A is linked to neoplasm.